Doing interesting drug trials, with a near-term opportunity for their orphan drug Placminogen, a specialty protein. With Placminogen they can basically sell almost everything they can produce. Earnings estimates for 2019 is basically zero. You are buying this for 2 reasons. 1.) The manufacturing process; buying a bag of plasma for $120, breaking out a large number of proteins, and selling it over time for about $1000. 2.) their drug PBI4050 which is targeted towards fibrosis, where early results are quite positive. To develop a drug and go through phase 2 and 3 drug trials, is extremely expensive. If your time frame is 3 years, he thinks you will be happy. A speculative company working with some very interesting drug opportunities.

On a payout basis, it has a modest 12% of 4th quarter trailing cash flow, so it looks like the dividend is sustainable. Cash flow for 2017 is expected to be pretty reasonable at $3, with about a 10% increase next year to $3.36. Because there is growth, it looks like the dividend is sustainable. If oil has bottomed at $42 and heads towards $50, there is a reasonable opportunity. Dividend yield of 3.9%.

This makes very interesting crystals that are used for PTE medical scanners. The real opportunity near term, is that they have signed an exclusive deal with a Chinese PTE manufacturer. It is a huge business growth opportunity in China. There has been some significant improvement in the last month or so, because they are not only using these for medical scanners, but they now have industrial applications. Working with a German automaker on a 3-D heads-up display. Also, there is the potential that Phillips may come back to the PTE medical scanner market. The terms of the dropped lawsuit was that Phillips would be required to buy this company’s crystals.

Recently acquired some US cable operations. Earnings per share were up 37%, a 4% earnings surprise. Free cash flow was up 113% year over year. Free cash flow yield increased from 6.5% last year to 10.4% this year. Trailing ROE is 21%. PE to growth is .35. Dividend yield of 2.1%. (Analysts’ price target is $82.50.)

Garbage is relatively recession proof. Earnings were up 79%. Year-over-year sales are pretty good. Free cash flow is up 77%. Free cash flow yield at 3.5% is an improvement from 2.5% of last year. ROE is 9%. Dividend yield of 0.8%. (Analysts’ price target is $72.)

A large company with almost 36,000 employees and 500 offices in 40 countries. 36% payout ratio. They are forecasting unchanged earnings at $.65. Growth margins grew from last year from 17.8% to 18.8%. Year-over-year cash flow was up 53%. Feels all infrastructure supporting companies will end up doing well. Dividend yield of 2.9%. (Analysts’ price target is $54.50.)

Take some profits or be a buyer? This has contracted a bit again. The main problem is that you don’t really get too much presence of them in the marketplace compared to their beginning. An issue that is difficult to handle is that they are going to split into 2 companies in a few months. When they split, that would suggest that instead of having an itsy-bitsy $.38 stock you are going to have 2 itsy-bitsy $.20 stocks. One is probably going to be dealing with sleep apnea type stuff and the other with the traditional home monitoring, which is still really experimental. He would probably underweight this until he could see the whites of their eyes.